Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair
Related Experiment Video
Updated: May 14, 2026

Measuring DNA Damage and Repair in Mouse Splenocytes After Chronic In Vivo Exposure to Very Low Doses of Beta- and Gamma-Radiation
Published on: July 3, 2015
B Groselj1, N L Sharma, F C Hamdy
1Department of Oncology, Gray Institute for Radiation Oncology and Biology, University of Oxford, Old Road Campus Research Building, Off Roosevelt Drive, Oxford, OX3 7DQ, UK.
Abstract:
Many cancers display increased expression of histone deacetylases (HDACs) and therefore transcriptionally inactive chromatin, resulting in the downregulation of genes including tumour suppressor and DNA repair genes. Histone deacetylase inhibitors (HDACi) are a heterogeneous group of epigenetic therapeutics, showing promising anticancer effects in both pre-clinical and clinical settings, in particular the effect of radiosensitisation when administered in combination with radiotherapy. Radiotherapy remains one of the most common forms of cancer treatment, leading to cell death through the induction of DNA double-strand breaks (DSBs). Cells have developed mechanisms to repair such DSB through two major pathways: non-homologous end-joining and homologous recombination. Here, we explore the current evidence for the use of HDACi in combination with irradiation, focusing on the effects of HDACi on DNA damage signalling and repair in vitro. In addition, we summarise the clinical evidence for using HDACi with radiotherapy, a growing area of interest with great potential clinical utility.
Insights
Histone deacetylase inhibitors (HDACi) enhance cancer radiotherapy by affecting DNA damage repair. This review explores HDACi
Area of Science:
- Epigenetics
- Cancer Biology
- Radiation Oncology
Background:
- Cancers often exhibit increased histone deacetylases (HDACs), leading to inactive chromatin and suppressed tumor suppressor genes.
- Histone deacetylase inhibitors (HDACi) are epigenetic drugs with demonstrated anticancer effects.
- HDACi show particular promise in radiosensitizing cancer cells when combined with radiotherapy.
Purpose of the Study:
- To review the evidence for combining HDAC inhibitors with irradiation.
- To focus on the in vitro effects of HDACi on DNA damage signaling and repair.
- To summarize clinical evidence for HDACi and radiotherapy combinations.
Main Methods:
- Exploration of current evidence on HDACi and irradiation combinations.
- Focus on in vitro studies of HDACi's impact on DNA damage response pathways.
- Summary of existing clinical trial data for combined modality treatment.
Main Results:
- HDACi influence DNA damage signaling and repair mechanisms in cancer cells.
- Pre-clinical and clinical data suggest radiosensitizing effects of HDACi.
- Combination of HDACi with radiotherapy is a promising therapeutic strategy.
Conclusions:
- HDAC inhibitors represent a valuable addition to radiotherapy for cancer treatment.
- Understanding HDACi's role in DNA repair is crucial for optimizing combination therapies.
- Further clinical investigation of HDACi and radiotherapy is warranted.
Related Concept Videos
DNA Damage Can Stall the Cell Cycle
DNA Damage can Stall the Cell Cycle
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Nucleotide Excision Repair
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
Overview of DNA Repair
Chemically...

